Duality Biotherapeutics, Inc. (HKG:9606)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Biotechnology	1.85B	1.94B	1.79B
Biotechnology Growth	-4.61%	8.66%	-
Total	1.85B	1.94B	1.79B
Total Growth	-4.61%	8.66%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
China	1.85B	1.94B	1.79B
China Growth	-4.61%	8.66%	-
Total	1.85B	1.94B	1.79B
Total Growth	-4.61%	8.66%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 14, 2026

Data Sources Report a data error